Patent 12245997

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Active provider: Google · gemini-2.5-flash

Ownership chain (1)

Asserters network →

Structured records extracted from the assignment-history narrative below. Each entity links to its full ownership-network profile.

  1. 2021-03-19 · recorded 2021-04-09 · reel 055880/0164 · ASSIGNMENT OF ASSIGNORS INTEREST

    AHMAD, ATEEQ; AHMAD, IMRAN; AHMAD, MOGHISUDDIN; ALI, SHOUKATH M; SHEIKH, SAIFUDDINJINA PHARMACEUTICALS, INC., ILLINOIS

    original assignment

Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

✓ Generated

Inventors

  • Ateeq Ahmad (Jina Pharmaceuticals Inc.)
  • Imran Ahmad (Jina Pharmaceuticals Inc.)
  • Moghisuddin AHMAD (Jina Pharmaceuticals Inc.)
  • Shoukath M ALI (Jina Pharmaceuticals Inc.)
  • Saifuddin Sheikh (Jina Pharmaceuticals Inc.)

All inventors appear to have been affiliated with the original assignee, Jina Pharmaceuticals Inc., at the time of filing. There is no information to suggest inventors departing the original assignee within 12 months of filing.

Original assignee

The original assignee is Jina Pharmaceuticals Inc. Based on the patent title, "Endoxifen for the treatment of bipolar I disorder," their primary line of business appears to be pharmaceutical research and development, specifically in the area of treatments for neurological disorders. It is unclear from the provided information whether Jina Pharmaceuticals Inc. currently ships a product embodying the claims of US12245997. The patent's legal status is "Active."

Assignment timeline

The USPTO Assignment Center (https://assignmentcenter.uspto.gov/) shows the following assignment for US12245997:

  • 2021-03-19 (executed) / recorded 2021-04-09 — Reel 055880/0164
    • Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST
    • Assignor: AHMAD, ATEEQ; AHMAD, IMRAN; AHMAD, MOGHISUDDIN; ALI, SHOUKATH M; SHEIKH, SAIFUDDIN
    • Assignee: JINA PHARMACEUTICALS, INC., ILLINOIS
    • Correspondent: Not explicitly listed in the reel/frame summary, but associated with the initial filing by Jina Pharmaceuticals Inc.
    • Context: Original assignment from inventors to the initial assignee.

As of the current date, no further assignments are recorded for US12245997 at the USPTO Assignment Center beyond the initial assignment from the inventors to Jina Pharmaceuticals Inc.

Timeline diagram

timeline
    title Ownership of US 12245997
    2021 : Filed by Jina Pharmaceuticals Inc.
         : Inventors assigned to Jina Pharmaceuticals Inc.
    2025 : Issued to Jina Pharmaceuticals Inc.
    2025 : PGR2026-00015 filed against Jina Pharma
    2026 : PGR case settled

NPE / troll-pattern signals

  1. Shell-entity transfer — not present. The patent remains with Jina Pharmaceuticals Inc., which appears to be an operating company engaged in pharmaceutical research and development, offering therapeutic products for various diseases.
  2. Known asserter in the chain — not present. Jina Pharmaceuticals Inc. is not listed as a known NPE.
  3. Repeat correspondent across the chain — not present. Only one assignment is recorded, so there is no chain to observe for recurring correspondents.
  4. Cascading transfers — not present. Only one assignment is recorded.
  5. Pre-litigation transfer — not present. The patent was assigned from inventors to Jina Pharmaceuticals Inc. prior to issuance and well before the PGR filing. The PGR itself was filed against Jina Pharmaceuticals Inc.
  6. Bankruptcy fire-sale — not present. There is no indication that Jina Pharmaceuticals Inc. has filed for bankruptcy.
  7. Privateering — unclear. While Jina Pharmaceuticals Inc. appears to be an operating company, the recent settlement of the PGR case with Atossa Therapeutics Inc. (a competitor in the Endoxifen space) suggests potential competitive activity. However, there is no direct evidence of a privateering arrangement.
  8. Defensive aggregator (anti-NPE) — not present. The patent is currently owned by Jina Pharmaceuticals Inc.

Verdict

Operating-company assertion The patent is currently held by Jina Pharmaceuticals Inc., an active pharmaceutical company engaged in the research, development, and commercialization of therapeutic products. The litigation history indicates Jina Pharmaceuticals Inc. as a defendant in a PGR initiated by Atossa Therapeutics Inc., a competitor, which suggests the patent is being defended by an operating company in a competitive landscape, rather than being asserted by an NPE. The recent settlement further supports this, as it involves the parties agreeing not to challenge specified endoxifen-related patents.

USPTO Assignment Center search for US12245997: https://assignmentcenter.uspto.gov/

Generated 5/27/2026, 6:46:29 PM